Annual report pursuant to Section 13 and 15(d)

Deferred Research And Development Arrangement (Details)

v2.4.1.9
Deferred Research And Development Arrangement (Details) (USD $)
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2003
Nov. 27, 2012
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Deferred Research and Development Arrangement $ 600,000rnn_DeferredResearchAndDevelopmentArrangement $ 833,630rnn_DeferredResearchAndDevelopmentArrangement    
Restricted Cash and Cash Equivalents, Noncurrent   196,130us-gaap_RestrictedCashAndCashEquivalentsNoncurrent    
Rexgene [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development arrangement, one-time fee     1,500,000us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
/ us-gaap_CounterpartyNameAxis
= rnn_RexgeneMember 		 
Reduction of research and development expenses 75,000rnn_ResearchAndDevelopementAgreementPeriodExpenseReductionAmount
/ us-gaap_CounterpartyNameAxis
= rnn_RexgeneMember 		75,000rnn_ResearchAndDevelopementAgreementPeriodExpenseReductionAmount
/ us-gaap_CounterpartyNameAxis
= rnn_RexgeneMember 		   
Research and development period 20 years      
Deferred Research and Development Arrangement 600,000rnn_DeferredResearchAndDevelopmentArrangement
/ us-gaap_CounterpartyNameAxis
= rnn_RexgeneMember 		675,000rnn_DeferredResearchAndDevelopmentArrangement
/ us-gaap_CounterpartyNameAxis
= rnn_RexgeneMember 		   
Royalties paid, percentage of net sales 3.00%rnn_ResearchAndDevelopementAgreementRoyaltyPercentageOfNetSales
/ us-gaap_CounterpartyNameAxis
= rnn_RexgeneMember 		     
Teva Pharmaceutical Industries, Ltd. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Reduction of research and development expenses 158,630rnn_ResearchAndDevelopementAgreementPeriodExpenseReductionAmount
/ us-gaap_CounterpartyNameAxis
= rnn_TevaPharmaceuticalIndustriesLtdMember 		     
Deferred Research and Development Arrangement   158,630rnn_DeferredResearchAndDevelopmentArrangement
/ us-gaap_CounterpartyNameAxis
= rnn_TevaPharmaceuticalIndustriesLtdMember 		   
Restricted Cash and Cash Equivalents, Noncurrent       $ 926,000us-gaap_RestrictedCashAndCashEquivalentsNoncurrent
/ us-gaap_CounterpartyNameAxis
= rnn_TevaPharmaceuticalIndustriesLtdMember